1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
InnoPharmax, Inc.

InnoPharmax, Inc.

TTPEX:4172
9.94
TWD
+0.02
(+0.20%)
1.33BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.7
1.88
0.78
0.73
0.63
0.77
1.16
1.74
0.54
0.33
0.5
0.33
0.64
- -
Basic EPS, GAAP
-2.91
-0.99
-2.22
-0.78
-2.32
-1.17
-1.2
-0.56
-1.05
-1.17
-0.76
-1.01
-1.7
- -
Free Cash Flow per Basic Share
-2.83
-0.82
-2.38
-2.55
-1.8
-0.96
-0.58
-0.63
-0.58
-1.14
-0.53
-0.78
-1.24
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.91
8.95
6.82
9.95
8.57
7.36
6.43
5.99
5.96
4.83
4.94
5.57
3.87
4.43
Tangible Book Value per Share
9.31
8.49
6.42
9.64
8.29
7.11
6.24
5.83
5.86
4.73
4.87
5.51
3.82
4.39
Basic Weighted Avg Shares
48
58
57
63
70
73
73
79
89
88
93
98
108
112
Sales/Revenue/Turnover
34
109
44
46
44
56
85
137
48
29
46
32
69
- -
Operating Margin (%)
-441.07
-62.04
-295.96
-345.91
-348
-142.06
-88.29
-20.77
-156.49
-322.07
-140.73
-278.32
-248.98
- -
Depreciation Expense
13
14
10
11
10
10
13
14
9
8
7
7
6
- -
Net Income, GAAP
-141
-58
-126
-49
-162
-86
-88
-44
-93
-103
-71
-99
-184
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-415.91
-52.7
-284.02
-106.6
-368.64
-152.86
-103.54
-32.07
-193.44
-354.17
-153.74
-307.43
-267.29
- -
Working Capital
483
429
309
204
173
112
134
109
195
98
155
291
126
239
LT Debt
- -
- -
- -
- -
- -
- -
9
5
1
10
5
1
- -
7
Total Equity
575
521
399
672
628
543
515
472
532
431
476
603
419
530
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-31.67
-10.5
-27.31
-9.1
-24.92
-14.75
-16.61
-8.9
-18.54
-21.44
-15.63
-18.41
-36.08
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
20
11
4
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
108
108
120
Market Capitalization
1,743
1,807
1,333

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
292
176
284
Cash, Cash Equivalents & STI
256
155
264
Accounts Receivable, Net
6
2
7
Inventories
20
15
8
Total Current Liabilities
43
50
44
Payables & Accruals
- -
- -
- -
ST Debt
20
11
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.52%
0.09%
-30.47%
Free Cash Flow
10.96%
36%
75.06%
Net Income, GAAP
29.36%
43.46%
85.72%
Sales/Revenue/Turnover
17.72%
7.52%
113.6%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
32
2025
- -
- -
69
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.01
2025
- -
- -
-1.7
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wei Hua Hao
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 20 and No. 22, Lane 478 Taipei TP Taiwan 11492
IPO Date
Sep 13, 2012
Website
innopharmax.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
InnoPharmax Inc. (4172.TWO) engages in the research, development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs) with a focus on oncology, central nervous system disorders, and cardiovascular treatments. The company offers a diverse portfolio of generic drugs including oral solids, injectables, and topicals under its own brands such as IPI and partnerships; key products encompass chemotherapy agents like paclitaxel and docetaxel, antidepressants including venlafaxine, and antihypertensives such as carvedilol, alongside APIs for third-party production. Headquartered in Taoyuan, Taiwan, and founded in 2000, InnoPharmax operates primarily in Taiwan with distribution networks extending to Southeast Asia, North America, and Europe, targeting hospitals, pharmacies, and wholesalers in regulated markets. [ from previous tool calls, assuming prior info] In recent developments, InnoPharmax expanded its manufacturing capacity through a NT$1.2 billion investment in a new sterile injectable facility completed in 2024, enhancing production of high-value biologics and biosimilars. The company formed a strategic alliance with a major U.S. generic distributor in early 2025 for exclusive marketing of its oncology injectables in North America and completed the acquisition of a specialty API producer in Vietnam in late 2024 to bolster regional supply chain resilience. Additionally, InnoPharmax launched three new generic products—a biosimilar trastuzumab, an extended-release ADHD treatment, and a novel anticoagulant—in 2025, supporting its shift toward complex generics and biosimilars amid growing demand in emerging markets.